Cancer Immunotherapy: Clinical Lessons to New Modalities (X3)
March 16-19, 2025
| Fairmont Banff Springs, Banff, AB, Canada
Christian U Blank, Stefani Spranger and Anna Christina Obenauf
Scholarship Deadline: Dec. 10, 2024 | Abstract Deadline: Feb. 21, 2025 | Early Registration Deadline: Jan. 29, 2025
| 4:00–8:00 PM |
Registration |
Van Horne Foyer |
| 6:00–8:00 PM |
Welcome Mixer |
Van Horne Foyer |
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–9:30 AM |
Welcome and Keynote Session (Joint) |
Van Horne A |
| |
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Session Chair |
|
| |
* Katy Rezvani, University of Texas MD Anderson Cancer Center
Session Chair |
|
| |
Carl H. June, University of Pennsylvania
Cell Therapies: Current State of the Art |
|
| |
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer |
|
| 9:30–9:50 AM |
Coffee Break |
Van Horne Foyer |
| 9:50–9:55 AM |
Award Recipient Acknowledgement |
Van Horne A |
| 9:55–12:00 PM |
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint) |
Van Horne A |
| |
* Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR T Cell Driven Dysfunction |
|
| |
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination Therapies to Stimulate the APC Compartment |
|
| |
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies |
|
| |
Christopher Harvey, Phenomic
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers |
|
| 12:00–1:00 PM |
Poster Setup |
Van Horne C |
| 12:00–3:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Van Horne C |
| 3:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
Van Horne B |
| |
Lauren E Milling, Harvard Medical School
A STUB1-CHIC2 Complex Decreases IL-27Rα Expression on CD8+ T Cells To Restrain Tumor Immunity |
|
| |
Alice O Kamphorst, Icahn School of Medicine at Mount Sinai
ICOS Limits Memory-like Properties and Function of Exhausted PD-1+ CD8 T Cells |
|
| |
* Derek A Wainwright, Loyola University Chicago Stritch School of Medicine
IDO1 - Revising Dogma to Improve Control |
|
| |
Henrique Borges da Silva, Mayo Clinic Arizona
The eATP Receptor P2RX7 Promotes Optimal Progenitor Exhausted CD8+ T Cell Responses To Anti-PD1 Blockade |
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–7:00 PM |
DC and Alternative Immune Cell Activation |
Van Horne B |
| |
* Amy C. Fan, UCSF
Interrogating Immune Archetypes & Tumor Sampling to Inform Therapy |
|
| |
Susan M Kaech, The Salk Institute
Metabolic Control of Anti-Tumor Immunity |
|
| |
Cansu Cimen Bozkus, Icahn School of Medicine at Mount Sinai
Personalized Neoantigen Vaccines in Cancer Immunotherapy |
|
| |
Joanna Pozniak, VIB
Short Talk: Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma With an Immune-Excluded Phenotype |
|
| |
Fiona Chatterjee, Massachusetts Institute of Technology
Short Talk: Tumor-resident CD103+ CD11b+ Dendritic Cells are Associated with Poor Anti-Tumor Immunity in Ovarian Cancer |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
President's Hall |
| 7:30–10:00 PM |
Poster Session 1 |
Van Horne C |
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–10:15 AM |
Neoadjuvant Cancer Immunotherapy, Where are We Standing |
Van Horne B |
| |
* Tina Cascone, University of Texas MD Anderson Cancer Center
Neoadjvant Cancer Immunotherapy in NSCLC |
|
| |
Christian U Blank, Netherlands Cancer Institute - NKI-AVL
Personalized Neoadjuvant Cancer Immunotherapy in Melanoma |
|
| |
Philip Georg Demaerel, UZLeuven
Short Talk: Insights from Single-Cell Resolution Spatial Transcriptomic Analysis Before and During Neoadjuvant Immunotherapy in Advanced Melanoma |
|
| |
Nicholas J Salgia, Roswell Park Comprehensive Cancer Center
Short Talk: Untangling and Applying the Paradoxical Immune Sensitivity of Sarcomatoid Renal Cell Carcinoma |
|
| |
Jaroslav Zak, University of Utah
Short Talk: Mechanistic Insights into the Paradoxical Efficacy of JAK and PD1 Inhibition in Cancer Immunotherapy |
|
| 9:00–9:20 AM |
Coffee Break |
Van Horne Foyer |
| 10:15–5:00 PM |
On Own for Lunch |
|
| 11:00–1:00 PM |
Poster Setup |
Van Horne C |
| 1:00–10:00 PM |
Poster Viewing |
Van Horne C |
| 3:00–4:30 PM |
Career Roundtable (Joint) |
Van Horne B |
| |
Wolfgang Karl Kastenmueller, Institute of Systems Immunology, Max-Planck Research Group
Professor and Director |
|
| |
Rayne H. Rouce, Baylor College of Medicine
Associate Professor |
|
| |
Kristian Hedstrom, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Chief Scientific Officer |
|
| |
Frank P Stegmeier, Curie.Bio
CSO Partner |
|
| |
Fabiola V Rivas, Immunity
Deputy Editor |
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–7:00 PM |
Integrative Strategies in Cancer Immunotherapy: Harnessing Myeloid Cells, NK Cells, Unconventional T Cells and More |
Van Horne B |
| |
* Stefani Spranger, Massachusetts Institute of Technology
DC Determine Quality of T Cell Responses |
|
| |
Wolfgang Karl Kastenmueller, Institute of Systems Immunology, Max-Planck Research Group
Affinity Selection Phase during CD8 T Cell Priming |
|
| |
Ann F. Cheung, Dragonfly Therapeutics
NK Cell Therapeutics |
|
| |
Chenyu Zhang, University of California, Berkeley
Short Talk: Intra-tumoral Treg Ablation Activates a CD4-NK Cell Axis to Control MHC Class I-deficient Tumors |
|
| |
Richard P. Tobin, University of Colorado Anschutz Medical Campus
Short Talk: Alterations in MAIT Cells Frequency and Function During Melanoma Development and Treatment |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
President's Hall |
| 7:30–10:00 PM |
Poster Session 2 |
Van Horne C |
Wednesday, March 19, 2025
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–11:00 AM |
Cytokine/Chemokine Biology and Engineering |
Van Horne B |
| |
Howard L. Kaufman, Massachusetts General Hospital and Ankyra Therapeutics
Remote Presentation: Anchored Cytokines for the Treatment of Cancer |
|
| |
Joanna R Groom, Walter and Eliza Hall Institute of Medical Research
Chemokine Signaling and Positioning in the LN |
|
| |
* Jamie Spangler, Johns Hopkins University
Cytokine Engineering |
|
| |
Sameer Chopra, Werewolf Therapeutics Inc.
Short Talk: Unmasking the Potential of Cytokines for Cancer Immunotherapy: Lessons Learned from the Early Clinical Development of Tumor-activated IL-2 and IL-12 INDUKINE Molecules |
|
| |
Xinyi Tu, Mayo Clinic
Short Talk: A New PD-L1 Antibody Degrades PD-L1 and Sensitizes Cancer Cells to Cytotoxic Therapy |
|
| |
Michelle Nathalie von Locquenghien, Weizmann Institute of Science
Short Talk: Development of Novel “Myeloid-Targeted Immunocytokine and (NK)T cell Enhancer” (MiTE) with Tumor-Conditioned Cytokine Activity for Cancer Treatment Using Single Cell Genomics and AI |
|
| 9:00–9:20 AM |
Coffee Break |
Van Horne Foyer |
| 11:00–3:15 PM |
On Own for Lunch |
|
| 3:15–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
Van Horne B |
| |
* Ana Marcu, Genentech
Developing Discovery Proteomics Technologies to Elucidate HLA Neoantigen Presentation |
|
| |
Feng Han, DKFZ (German Cancer Research Center)
CMTM4/6 as Novel Therapeutic Targets to Sensitize Hepatocellular Carcinoma to Immunotherapy |
|
| |
Caitlin O'Brien-Ball, University of Oxford
Characterising Novel Protein Tools for Potentiating T Cell Activation by Inhibiting PD-1 |
|
| |
Amanda G Heard, University of Kansas Medical Center
Progesterone Promotes Immunosuppression in Murine Mammary Tumors by Modulating T Cell Infiltration and Function |
|
| |
Trevor E Frederick, Rutgers University
Novel Type I-Type III IFN Fusion Proteins For Cancer Therapy |
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–6:30 PM |
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint) |
Van Horne A |
| |
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Remote Presentation: Engineering of Myeloid Cells |
|
| |
Jaehyuk Choi, Northwestern University
Nature Inspired Design |
|
| |
* Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy |
|
| 6:30–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint) |
Van Horne A |
| 7:00–8:00 PM |
Social Hour with Lite Bites |
President's Hall |
| 8:00–9:00 PM |
Entertainment |
Van Horne B |
